Epstein-barr virus and MS

International MS Journal

Volumn 17, Issue 2, 2011, Pages 44-49

  Giovannoni, G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Causation; Complex disease; Epstein barr virus; Multiple sclerosis

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; HLA DR ANTIGEN; HLA DR15 ANTIGEN; IMMUNOGLOBULIN G; LATENT MEMBRANE PROTEIN 1; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN;

ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; CAUSAL ATTRIBUTION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD HEALTH; CLUSTER ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE ACTIVITY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; GENETIC SUSCEPTIBILITY; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; INFECTIOUS MONONUCLEOSIS; LYMPHOCYTE TRANSFORMATION; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; SEROCONVERSION; SEROPREVALENCE; DEMOGRAPHY; EPSTEIN BARR VIRUS INFECTION; GENETICS; PERSONNEL;

ANTIBODIES, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MULTIPLE SCLEROSIS; RESEARCH PERSONNEL; RESIDENCE CHARACTERISTICS;

EID: 79959765216     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Giovannoni G, Ebers G. Multiple sclerosis: the environment and causation. Curr Opin Neurol 2007; 20:261-268.
2. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7:268-277.
3. Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 2008; 28:17-28.
4. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007; 61:288-299.
5. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000; 11: 220-224.
6. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006; 59:499-503.
7. Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007; 6:773-781.
8. Pohl D, Krone B, Rostasy K, et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006; 67:2063-2065.
9. Giovannoni G, Cutter GR, Lunemann J, et al. Infectious causes of multiple sclerosis. Lancet Neurol 2006; 5:887-894.
10. Levin LI, Munger K, O'Reillly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Annals of Neurology 2010; In Press.
11. Fraser KB, Haire M, Millar JH, McCrea S. Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet 1979; 2:175-176.
12. Nielsen TR, Rostgaard K, Nielsen NM, et al. Multiple sclerosis after infectious mononucleosis. Arch Neurol 2007; 64:72-75.
13. Ramagopalan SV, Valdar W, Dyment DA, et al. Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology 2009; 32:257-262.
14. Sundstrom P, Juto P, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004; 62: 2277-2282.
15. Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005; 293:2496-2500.
16. Norrby E. Viral antibodies in multiple sclerosis. Prog Med Virol 1978; 24:1-39.
17. Munch M, Hvas J, Christensen T, Moller-Larsen A, Haahr S. A single subtype of Epstein-Barr virus in members of multiple sclerosis clusters. Acta Neurol Scand 1998; 98:395-399.
18. Lindsey JW, Patel S, Zou J. Epstein-Barr virus genotypes in multiple sclerosis. Acta Neurol Scand 2008; 117:141-144.
19. Brennan R, Burrows J, Bell M, et al. Strains of Epstein-Barr virus infecting multiple sclerosis patients. Mult Scler 2010; 16: 643-651.
20. Rand KH, Houck H, Denslow ND, Heilman KM. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci 2000; 173:32-39.
21. Bray P F, Luka J, Bray P F, Culp KW, Schlight J P. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 1992; 42: 1798-1804.
22. Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005; 115:1352-1360.
23. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204:2899-2912.
24. Pohl D, Rostasy K, Jacobi C, et al. Intrathecal antibody production against Epstein-Barr and other neurotropic viruses in pediatric and adult onset multiple sclerosis. J Neurol 2009; 257: 212-216.
25. Jaquiery E, Jilek S, Schluep M, et al. Intrathecal immune responses to Epstein-Barr virus in early multiple sclerosis. Eur J Immunol 2009. [more details required].
26. Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3:940-943.
27. van Sechel AC, Bajramovic JJ, van Stipdonk MJ, Persoon-Deen C, Geutskens SB, van Noort JM. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 1999; 162:129-135.
28. van Noort JM, van Sechel AC, Bajramovic JJ, et al. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995; 375:798-801.
29. Hollsberg P, Hansen HJ, Haahr S. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 2003; 132: 137-143.
30. Lunemann JD, Edwards N, Muraro PA, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006; 129:1493-1506.
31. Hjalgrim H, Rasmussen S, Rostgaard K, et al. Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst 2004; 96:780-784.
32. Wandinger K, Jabs W, Siekhaus A, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000; 55: 178-184.
33. Buljevac D, van Doornum GJ, Flach HZ, et al. Epstein-Barr virus and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76:1377-1381.
34. Farrell RA, Antony D, Wall GR, et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009; 73: 32-38.
35. Zivadinov R, Zorzon M, Weinstock-Guttman B, et al. Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80:620-625.
36. Lunemann JD, Tintore M, Messmer B, et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 2010; 67:159-169.
37. Willis SN, Stadelmann C, Rodig SJ, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009; 132: 3318-3328.
38. Peferoen LA, Lamers F, Lodder LN, et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 2009; 133:e137.
39. Torkildsen O, Stansberg C, Angelskar SM, et al. Upregulation of Immunoglobulin-related Genes in Cortical Sections from Multiple Sclerosis Patients. Brain Pathol 2009; 20: 720-729.
40. de Jager PL, Simon KC, Munger KL, Rioux JD, Hafler DA, Ascherio A. Integrating risk factors. HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008. 70: 1113-1118.
41. Sundstrom P, Nystrom M, Ruuth K, Lundgren E. Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis. J Neuroimmunol 2009; 215: 102-107.
42. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997; 100: 3019-3026.
43. Cooke S P, Rigby S P, Griffiths DJ, Venables PJ. Viral studies in rheumatic disease. Ann Med Interne 1998; 149:30-33.
44. Pender M P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003; 24:584-588.
45. Christensen T. Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev Med Virol 2005; 15:179-211.
46. Munch M, Moller-Larsen A, Christensen T, Morling N, Hansen HJ, Haahr S. B-lymphoblastoid cell lines from multiple sclerosis patients and a healthy control producing a putative new human retrovirus and Epstein-Barr virus. Mult Scler 1995; 1:78-81.
47. Perron H, Lazarini F, Ruprecht K, et al. Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions. J Neurovirol 2005; 11:23-33.
48. Koch R. The aetiology of tuberculosis (translation of Die Aetiologie der Tuberculose [1882]). New York: Dover Publications; 1942.
49. Fredericks DN, Relman DA. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. Clin Microbiol Rev 1996; 9:18-33.
50. Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med 1965; 58:295-300.